CDH2 and neoplasm: These cytokines activate signaling pathways such as SMAD, STAT3, and NF-κB in tumor cells, leading to the downregulation of epithelial markers like E-cadherin and the upregulation of mesenchymal markers such as vimentin and N-cadherin [[14], [15], [16]].